Cure rate of low-risk superficial basal cell carcinoma treated with topical 5-fluorouracil
DOI:
https://doi.org/10.29176/2590843X.1834Keywords:
5-fluorouracil, Non melanoma skin cancer, Superficial basal cell carcinoma, Topical chemotherapy, TreatmentAbstract
Background: Basal cell carcinoma (BCC) is the most common cancer in the world making this condition a public health issue. Superficial BCC (sBCC) is a subtype with indolent behavior. The gold standard treatment is the surgical resection, however, sBCC can be treated with more cost-effective noninvasive therapies such as 5% 5-Fluorouracil (5-FU). The objective of this study was to evaluate the clinical cure rate, tolerability and satisfaction levels on patients featured intermediate pigmented skin in the treatment of low-risk superficial basal cell carcinoma with topical 5% 5-FU.
Methods: A prospective case series study was conducted between June 2014 and August 2018 at the dermatology service of Hospital de San José in Bogotá, Colombia with histologically-proven superficial BCC lesions. Lesions were treated with topical 5% 5-FU twice daily for up to 8 weeks. A follow-up evaluation was conducted at weeks four and eight during treatment. Follow-up was planned to be conducted every three months.
Results: The study included 19 patients with 23 biopsy-proven sBCC lesions. Twenty-two lesions completed treatment with 5% 5-FU cream. The follow-up period ranged between 7 and 48 months and the median follow-up time was 38 months (IQR 21-48). All study patients featured intermediate or higher pigmented skin. Clinical cure was achieved in 95.45% of treated lesions.
Conclusions: The efficacy rate of 5% 5-FU for 8 weeks treatment for sBCC located in intermediate and low-risk areas was 95% offering high levels of patient satisfaction with an outstanding tolerability profile.
Author Biographies
Camilo E Alarcón Pérez, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia
Dermatology Department, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia
Santiago A. Ariza-Gómez, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia
Department of Dermatologic Oncology, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia
Samuel D. Morales-Naranjo, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia
Department of Pathology, Fundación Universitaria de Ciencias de la Salud - FUCS, Bogotá, Colombia.
References
Berking C, Hauschild A, Kölbl O, Mast G, Gutzmer R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014;111 22:389-95.
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353 21:2262-9.
Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: A systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167 4:733-56.
Ariza S, Espinosa S, Naranjo M. Nonsurgical therapies for basal cell carcinoma: A review. Actas Dermosifiliogr. 2017;108 9:809-17.
Raasch B. Management of superficial basal cell carcinoma: Focus on imiquimod. Clin Cosmet Investig Dermatol. 2009;2:65-75.
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase iii, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50 5:722-33.
Ceilley RI. Mechanisms of action of topical 5-fluorouracil: Review and implications for the treatment of dermatological disorders. J Dermatolog Treat. 2012;23 2:83-9.
Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33 4:433-9; discussion 40.
de Vries E, Louwman M, Bastiaens M, de Gruijl F, Coebergh JW. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast netherlands since 1973. J Invest Dermatol. 2004;123 4:634-8.
Miller DL, Weinstock MA. Nonmelanoma skin cancer in the united states: Incidence. J Am Acad Dermatol. 1994;30 5 Pt 1:774-8.
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166 5:1069-80.
Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-García C, Rodríguez-Pazos L, Pastushenko I, et al. Skin cancer incidence and mortality in spain: A systematic review and meta-analysis. Actas Dermosifiliogr. 2016;107 4:318-28.
Jansen MHE, Mosterd K, Arits AHMM, Roozeboom MH, Sommer A, Essers BAB, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138 3:527-33.
Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (sins): A multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15 1:96-105.
Soong LC, Keeling CP. Cryosurgery + 5% 5-fluorouracil for treatment of superficial basal cell carcinoma and bowen's disease [formula: See text]. J Cutan Med Surg. 2018;22 4:400-4.
Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14 7:647-54.
Roozeboom MH, Arits AH, Mosterd K, Sommer A, Essers BA, de Rooij MJ, et al. Three-year follow-up results of photodynamic therapy vs. Imiquimod vs. Fluorouracil for treatment of superficial basal cell carcinoma: A single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136 8:1568-74.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Camilo E Alarcón Pérez, Santiago A. Ariza-Gómez, Samuel D. Morales-Naranjo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
